The Safety and Microbial Changes in the Use of Intranasal Neosporin®

The Safety and Microbial Changes in the Use of Intranasal Neosporin®: A Prospective Study

Neosporin is an over-the-counter, FDA-approved triple-antibiotic ointment. It is widely used to treat and prevent skin infections following minor burns and injuries. Although the Neosporin® prospect indicates its use is strictly topical, it is often used intranasally by ear, nose, and throat specialists, plastic surgeons, and intensivists to prevent and treat various conditions. Nonetheless, no literature has documented the safety of intranasal Neosporin®. We designed a prospective study to assess the safety of this intervention in healthy participants and to investigate microbial changes before and after the intervention. Healthy participants will apply Neosporin® intranasally for 15 days and record daily adverse events and their severity. Nasal cultures will be drawn before and after the intervention and compared.

Study Overview

• Status: Completed
• Conditions: Teste the Safety of (Polymyxin B Sulfate 500,000 IU, Bacitracin Zinc 40,000 IU, Neomycin Sulfate 0.35g Neomycin Base) Intranasally
• Intervention / Treatment: Drug: Intranasal application of Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Mexico
  • Nuevo León
    • Monterrey, Nuevo León, Mexico, 64460
      • Hospital Universitario "Dr. José Eleuterio González"

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age between 18 and 65 years
• Signed informed consent
• Healthy volunteers

Exclusion Criteria:

• Chronic or recurrent nasal conditions
• Current use of other intranasal medications
• History of severe allergic reactions to antibiotics
• History of allergy to the components of Neosporin®
• Participation in another research protocol
• Being a staff member or an immediate family member of a staff member
• Pregnant women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base; 0.5 gr of Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base will be applied intranasally in healthy participants for 15 days

Drug: Intranasal application of Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base; We want to test the safety of the intranasal application of Neosporin® (Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base) since it has not been tested. Sing and symptom diaries and nasal swabs for culture will be collected; Other Names: Signs and Symptoms diary completion; nasal swab culture

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Adverse events of intranasal Neosporin® in healthy participants.	16 days

Collaborators and Investigators

• Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
• Investigators: Study Director: Adrian Camacho Ortiz, MD, PhD, Hospital Universitario Dr. Jose Eleuterio González

Study record dates

Study Major Dates

• Study Start (Actual): February 13, 2025
• Primary Completion (Actual): March 22, 2025
• Study Completion (Actual): March 23, 2025

Study Registration Dates

• First Submitted: July 7, 2026
• First Submitted That Met QC Criteria: July 7, 2026
• First Posted (Actual): July 13, 2026

Study Record Updates

• Last Update Posted (Actual): July 14, 2026
• Last Update Submitted That Met QC Criteria: July 10, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: safety; Intranasal; Neosporin
• Additional Relevant MeSH Terms: Peptides; Amino Acids, Peptides, and Proteins; Carbohydrates; Polycyclic Compounds; Glycosides; Aminoglycosides; Macrocyclic Compounds; Peptides, Cyclic; Neomycin; Bacitracin
• Other Study ID Numbers: IF24-00009

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No